STING1 and neoplasm: applied low dose of STING agonist on a mouse melanoma subcutaneous tumor‐bearing model and found that tumoral TLS increased expression of antiangiogenic factors TNFSF15 and CXCL10 as well as TLS inducers such as CCL19/21, LTα/β, and LIGHT.